Anika Therapeutics Inc. (AKP)
XFRA 
Summary
AKP Chart
Anika Therapeutics, Inc. (ANIK) Q1 2025 Earnings Call Transcript
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Matt Hall - Director, Corporate Development & Investor Relations Cheryl Blanchard - President & Chief Executive Officer Steve Griffin - Executive Vice President, Chief Financial Officer & Chief Operating Officer Conference Call Participants Anderson Schock - B. Riley Securities Mike Petusky - Barrington Research Jim Sidoti - Sidoti & Company.
Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates
Anika Therapeutics (ANIK) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.09. This compares to loss of $0.31 per share a year ago.
Anika Reports First Quarter 2025 Financial Results
First Quarter 2025 Commercial Channel revenue up 18% Integrity ™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating Fiscal 2025 OEM Channel revenue guidance and Adjusted EBITDA guidance BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for the first quarter ended March 31, 2025.
Anika Therapeutics Inc. Dividends
Anika Therapeutics Inc. Earnings
| 6 Aug 2025 (54 Days) Date | | - Cons. EPS | - EPS |
| 6 May 2025 Date | | - Cons. EPS | - EPS |
| 11 Mar 2025 Date | | - Cons. EPS | - EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 6 Aug 2025 (54 Days) Date | | - Cons. EPS | - EPS |
| 6 May 2025 Date | | - Cons. EPS | - EPS |
| 11 Mar 2025 Date | | - Cons. EPS | - EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
Anika Therapeutics Inc. (AKP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Anika Therapeutics Inc. ever had a stock split?
Anika Therapeutics Inc. Profile
| Medical - Devices Industry | Healthcare Sector | Dr. Cheryl Renee Blanchard Ph.D. CEO | XFRA Exchange | US0352551081 ISIN |
| US Country | 288 Employees | - Last Dividend | - Last Split | 29 Apr 1993 IPO Date |
Overview
Anika Therapeutics, Inc. is recognized as a key player in the field of joint preservation, focusing its efforts on the early intervention in orthopedic care. The company's mission revolves around providing innovative solutions for osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions, serving a global market that includes the United States, Europe, and other international regions. The foundation of Anika Therapeutics' product development and commercialization strategies is its proprietary hyaluronic acid (HA) technology platform. The company was established in 1983 and has its headquarters located in Bedford, Massachusetts.
Products and Services
-
OA Pain Management Products
- Monovisc and Orthovisc: These are injectable HA-based viscosupplements designed to alleviate pain from osteoarthritis conditions, providing patients with a non-surgical treatment option.
- Cingal: A cutting-edge, single-injection OA pain management product combining HA with a corticosteroid to offer both immediate and sustained pain relief.
-
Joint Preservation and Restoration
- Hyalofast: A biodegradable support matrix used in the repair and regeneration of cartilage defects, employing the patient's own cells.
- Tactoset: An injectable bone substitute designed to heal bone defects and support bone regeneration, offering a unique solution for orthopedic regenerative needs.
- Sports Medicine Solutions: Includes a range of products used to repair and reconstruct damaged ligaments and tendons, facilitating the recovery of athletes and physically active individuals.
- Partial Joint Replacement and Joint Resurfacing Solutions: These solutions focus on preserving the joints by replacing or resurfacing only the damaged parts, thus maintaining as much of the natural joint structure as possible. They are designed for both upper and lower extremity conditions and aim to offer an alternative to more invasive procedures.
-
Non-Orthopedic Products
- Hyvisc: A high molecular weight injectable HA veterinary product designed for the treatment of joint dysfunction in horses.
- Hyalobarrier: An anti-adhesion gel indicated for use after abdominal-pelvic surgeries to prevent post-surgical adhesions.
- Hyalomatrix: A dermal matrix used to treat burns and ulcers, fostering an environment conducive to the healing of skin wounds.
- In addition, the company offers HA-based products for the treatment of ears, nose, and throat disorders, as well as ophthalmic products, further demonstrating the versatility of its HA technology in addressing a wide range of medical conditions.
Contact Information
